CRDL
Price
$1.04
Change
+$0.08 (+8.33%)
Updated
Dec 5, 04:59 PM (EDT)
Capitalization
95.31M
117 days until earnings call
Intraday BUY SELL Signals
KMDA
Price
$7.08
Change
-$0.03 (-0.42%)
Updated
Dec 5, 04:59 PM (EDT)
Capitalization
409.44M
102 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRDL vs KMDA

Header iconCRDL vs KMDA Comparison
Open Charts CRDL vs KMDABanner chart's image
Cardiol Therapeutics
Price$1.04
Change+$0.08 (+8.33%)
Volume$302
Capitalization95.31M
Kamada
Price$7.08
Change-$0.03 (-0.42%)
Volume$1.66K
Capitalization409.44M
CRDL vs KMDA Comparison Chart in %
CRDL
Daily Signal:
Gain/Loss:
KMDA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CRDL vs. KMDA commentary
Dec 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRDL is a Hold and KMDA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 06, 2025
Stock price -- (CRDL: $0.96 vs. KMDA: $7.11)
Brand notoriety: CRDL and KMDA are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: CRDL: 67% vs. KMDA: 59%
Market capitalization -- CRDL: $95.31M vs. KMDA: $408.11M
CRDL [@Pharmaceuticals: Generic] is valued at $95.31M. KMDA’s [@Pharmaceuticals: Generic] market capitalization is $408.11M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRDL’s FA Score shows that 0 FA rating(s) are green whileKMDA’s FA Score has 0 green FA rating(s).

  • CRDL’s FA Score: 0 green, 5 red.
  • KMDA’s FA Score: 0 green, 5 red.
According to our system of comparison, KMDA is a better buy in the long-term than CRDL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRDL’s TA Score shows that 3 TA indicator(s) are bullish while KMDA’s TA Score has 4 bullish TA indicator(s).

  • CRDL’s TA Score: 3 bullish, 6 bearish.
  • KMDA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, KMDA is a better buy in the short-term than CRDL.

Price Growth

CRDL (@Pharmaceuticals: Generic) experienced а -6.66% price change this week, while KMDA (@Pharmaceuticals: Generic) price change was +4.56% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.40%. For the same industry, the average monthly price growth was -0.87%, and the average quarterly price growth was +18.27%.

Reported Earning Dates

CRDL is expected to report earnings on Apr 01, 2026.

KMDA is expected to report earnings on Mar 18, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.40% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KMDA($409M) has a higher market cap than CRDL($95.3M). KMDA YTD gains are higher at: 20.094 vs. CRDL (-24.891). KMDA has higher annual earnings (EBITDA): 34.2M vs. CRDL (-39.94M). KMDA has more cash in the bank: 66M vs. CRDL (18.2M). CRDL has less debt than KMDA: CRDL (143K) vs KMDA (11.4M). KMDA has higher revenues than CRDL: KMDA (170M) vs CRDL (0).
CRDLKMDACRDL / KMDA
Capitalization95.3M409M23%
EBITDA-39.94M34.2M-117%
Gain YTD-24.89120.094-124%
P/E RatioN/A20.23-
Revenue0170M-
Total Cash18.2M66M28%
Total Debt143K11.4M1%
FUNDAMENTALS RATINGS
CRDL vs KMDA: Fundamental Ratings
CRDL
KMDA
OUTLOOK RATING
1..100
1013
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10078
PRICE GROWTH RATING
1..100
8551
P/E GROWTH RATING
1..100
10055
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRDL's Valuation (72) in the null industry is in the same range as KMDA (73) in the Biotechnology industry. This means that CRDL’s stock grew similarly to KMDA’s over the last 12 months.

CRDL's Profit vs Risk Rating (100) in the null industry is in the same range as KMDA (100) in the Biotechnology industry. This means that CRDL’s stock grew similarly to KMDA’s over the last 12 months.

KMDA's SMR Rating (78) in the Biotechnology industry is in the same range as CRDL (100) in the null industry. This means that KMDA’s stock grew similarly to CRDL’s over the last 12 months.

KMDA's Price Growth Rating (51) in the Biotechnology industry is somewhat better than the same rating for CRDL (85) in the null industry. This means that KMDA’s stock grew somewhat faster than CRDL’s over the last 12 months.

KMDA's P/E Growth Rating (55) in the Biotechnology industry is somewhat better than the same rating for CRDL (100) in the null industry. This means that KMDA’s stock grew somewhat faster than CRDL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRDLKMDA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
70%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
63%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
64%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
65%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
68%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
65%
Declines
ODDS (%)
Bearish Trend 16 days ago
87%
Bearish Trend 19 days ago
65%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CRDL
Daily Signal:
Gain/Loss:
KMDA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VRTTX584.670.86
+0.15%
Vanguard Russell 3000 Index I
NELAX64.830.08
+0.12%
Nuveen Equity Long/Short A
FEVIX25.79N/A
N/A
First Eagle US I
MAGCX32.33N/A
N/A
BlackRock Advantage Global Institutional
RYEUX125.66-0.52
-0.41%
Rydex Europe 1.25x Strategy H

CRDL and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRDL has been loosely correlated with EOLS. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if CRDL jumps, then EOLS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDL
1D Price
Change %
CRDL100%
+1.82%
EOLS - CRDL
35%
Loosely correlated
+0.89%
ACB - CRDL
33%
Poorly correlated
+0.66%
LNTH - CRDL
31%
Poorly correlated
+3.51%
SNOA - CRDL
29%
Poorly correlated
+12.97%
HIMS - CRDL
26%
Poorly correlated
+7.96%
More

KMDA and

Correlation & Price change

A.I.dvisor tells us that KMDA and LFCR have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KMDA and LFCR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KMDA
1D Price
Change %
KMDA100%
+0.28%
LFCR - KMDA
29%
Poorly correlated
+1.70%
OGI - KMDA
29%
Poorly correlated
-2.38%
SGIOY - KMDA
27%
Poorly correlated
+2.02%
RDY - KMDA
26%
Poorly correlated
+0.07%
CRDL - KMDA
25%
Poorly correlated
+1.82%
More